- Home
- BEAM vs USA Comparison
BEAM vs USA Comparison
Compare BEAM & USA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BEAM
- USA
- Stock Information
- Founded
- BEAM 2017
- USA 1986
- Country
- BEAM United States
- USA United States
- Employees
- BEAM N/A
- USA N/A
- Industry
- BEAM Biotechnology: Biological Products (No Diagnostic Substances)
- USA Finance Companies
- Sector
- BEAM Health Care
- USA Finance
- Exchange
- BEAM Nasdaq
- USA Nasdaq
- Market Cap
- BEAM 1.6B
- USA N/A
- IPO Year
- BEAM 2020
- USA N/A
- Fundamental
- Price
- BEAM $17.59
- USA $6.84
- Analyst Decision
- BEAM Strong Buy
- USA
- Analyst Count
- BEAM 11
- USA 0
- Target Price
- BEAM $48.90
- USA N/A
- AVG Volume (30 Days)
- BEAM 1.9M
- USA 880.5K
- Earning Date
- BEAM 08-05-2025
- USA 01-01-0001
- Dividend Yield
- BEAM N/A
- USA 9.66%
- EPS Growth
- BEAM N/A
- USA N/A
- EPS
- BEAM N/A
- USA N/A
- Revenue
- BEAM $63,578,000.00
- USA N/A
- Revenue This Year
- BEAM N/A
- USA N/A
- Revenue Next Year
- BEAM $8.82
- USA N/A
- P/E Ratio
- BEAM N/A
- USA N/A
- Revenue Growth
- BEAM N/A
- USA N/A
- 52 Week Low
- BEAM $13.53
- USA $5.62
- 52 Week High
- BEAM $35.25
- USA $7.09
- Technical
- Relative Strength Index (RSI)
- BEAM 45.97
- USA 63.59
- Support Level
- BEAM $16.49
- USA $6.64
- Resistance Level
- BEAM $17.73
- USA $6.85
- Average True Range (ATR)
- BEAM 0.87
- USA 0.07
- MACD
- BEAM 0.02
- USA 0.01
- Stochastic Oscillator
- BEAM 29.91
- USA 92.65
About BEAM Beam Therapeutics Inc.
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.